Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

US court rules against GSK in dispute with AnaptysBio

(Sharecast News) - A US court has granted a motion to dismiss filed by biotech AnaptysBio in a dispute with GSK's oncology unit, it was confirmed on Monday. Tesaro launched litigation against AnaptysBio in November, claiming it was in breach of its agreement regarding cancer treatment Jemperli. AnaptysBio countersued, and filed the partial motion to dismiss in January.

Dan Faga, chief executive of AnaptysBio, said: "The court's decision affirms what we have maintained from the beginning: Tesaro's anticipatory breach claim was baseless, and this ruling is an important validation of our efforts to protect our contractual rights to the Jemperli royalty stream for our shareholders."

However, GSK insisted that the ruling - made by the Delaware Chancery Court - did not address the merits of the principal contractual dispute between the parties, and that it had no impact on Tesaro's remaining claim against AnaptysBio for declaratory judgement.

"GSK and Tesaro are firmly of the view that these allegations are entirely without merit and remain focused on pursuing that claim at trial," it concluded.

AnaptysBio and Tesaro, which GSK acquired in 2019, signed the agreement to develop and sell Jemperli, the brand name for dostarlimab, in 2014. Jemperli is currently approved in over 35 countries for use in certain endometrial cancers.

However, Tesaro has accused AnaptysBio of breaching the agreement, thereby allowing it to terminate the deal, reduce royalty and milestone payments and secure a permanent licence to the drug.

AnaptysBio has countersued, accusing Tesaro of violating exclusivity terms.

Earlier in April, AnaptysBio became a royalty management company after it spun off its biopharma business as First Tracks Biotherapeutics. Its business is now focused on two specific deals, with GSK for Jemperli and with American firm Vanda Pharmaceuticals for imsidolimab.

See latest RNS on Investegate

Share this article

Related Sharecast Articles

Amazon gets go-ahead for wider UK drone delivery service
(Sharecast News) - Amazon's Prime Air drone delivery service has been granted regulatory approval to expand operations in the north-east of England, increasing the number of eligible households to 8,000 from around 600.
Metlen to sell portfolio of four UK solar parks to Nala Renewables
(Sharecast News) - Metlen Energy & Metals said on Tuesday that it has agreed to sell four solar parks in the UK with a combined capacity of around 119 MW to Nala Renewables.
Princes Group reaffirms outlook despite 'challenging' market backdrop
(Sharecast News) - Princes Group reaffirmed full-year guidance on Tuesday, after the tinned tuna specialist shrugged off tough market conditions to post a jump in third-quarter earnings.
Berenberg cuts AB Dynamics price target amid challenging automotive market
(Sharecast News) - Analysts at Berenberg reduced their target price on AB Dynamics to 1,350p from 1,700p on Tuesday following the group's full-year results, citing a tougher outlook for growth and margins amid continued disruption across the global automotive sector.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.